Edition:
India

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

4.46USD
25 Sep 2020
Change (% chg)

$0.18 (+4.21%)
Prev Close
$4.28
Open
$4.31
Day's High
$4.48
Day's Low
$4.30
Volume
21,013
Avg. Vol
103,339
52-wk High
$8.90
52-wk Low
$3.44

Select another date:

Mon, Jun 29 2020

BRIEF-Catalyst Biosciences Added To Russell 2000 Index

* CATALYST BIOSCIENCES ADDED TO RUSSELL 2000 INDEX Source text for Eikon: Further company coverage:

BRIEF-Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data In Oral Presentation At The World Federation Of Hemophilia Virtual Summit 2020

* CATALYST BIOSCIENCES PRESENTS PRECLINICAL FIX GENE THERAPY DATA IN AN ORAL PRESENTATION AT THE WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT 2020 Source text for Eikon: Further company coverage:

BRIEF-Assenagon Asset Management S.A. Reports 6.39% Passive Stake In Catalyst Biosciences Inc

* ASSENAGON ASSET MANAGEMENT S.A. REPORTS 6.39% PASSIVE STAKE IN CATALYST BIOSCIENCES INC AS OF JUNE 17 - SEC FILING Source text : (https://bit.ly/3fIHurl) Further company coverage:

BRIEF-Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Catalyst Bio - Plans To Initiate Phase 1/2 Trial Of Marzaa In Factor Vii Deficiency, Glanzmann Thrombasthenia, And Hemlibra Patients In Q4

* CATALYST BIO - PLANS TO INITIATE PHASE 1/2 TRIAL OF MARZAA IN FACTOR VII DEFICIENCY, GLANZMANN THROMBASTHENIA, AND HEMLIBRA PATIENTS IN Q4 Source text for Eikon: https://bit.ly/30Swx1W Further company coverage:

BRIEF-Catalyst Biosciences Appoints Clinton Musil As Chief Financial Officer

* CATALYST BIOSCIENCES APPOINTS CLINTON MUSIL AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Catalyst Presents Positive Final Data From Phase 2B Trial Of Subcutaneous Dalcinonacog Alfa

* CATALYST BIOSCIENCES PRESENTS POSITIVE FINAL DATA FROM ITS PHASE 2B TRIAL OF SUBCUTANEOUS DALCINONACOG ALFA (DALCA) AT THE WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT 2020 Source text for Eikon: Further company coverage:

BRIEF-Catalyst Biosciences Completes Marzaa Pharmacokinetic & Pharmacodynamic Study

* CATALYST BIOSCIENCES COMPLETES MARZAA PHARMACOKINETIC & PHARMACODYNAMIC STUDY

BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.28

* CATALYST BIOSCIENCES REPORTS FIRST QUARTER 2020 OPERATING & FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

Select another date: